My job and personal time are heavy on screen usage. While I’m not experiencing presbyopia yet, I’m wondering when it’s coming ...

An eye surgeon explains the factors accelerating eye problems in men in their 40s and the essential eye tests they must not ...

Opus Genetics ( ($IRD) ) has shared an update. On December 17, 2025, Viatris Inc., the commercialization partner for Phentolamine Ophthalmic ...

Investing.com -- LENZ Therapeutics (NASDAQ:LENZ) stock tumbled 25% on heavy volume Friday in New York after a case of retinal tear associated with its VIZZ eye drop appeared in the FDA’s adverse event ...

Advanced technology lenses work best in pristine eyes. Problems with ocular alignment, pupil size, ocular surface disease, irregular astigmatism, corneal dystrophies, scarring, and diseases of the ...

The NDA submission is based on findings from three randomised, double-masked, controlled Phase III studies carried out in the US.

Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, ...

SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

LENZ Therapeutics (LENZ) stock drops as an FDA database indicates an adverse event linked to the company's newly launched eye ...

As of Friday, December 19, LENZ Therapeutics, Inc.’s LENZ share price has surged by 5.60%, which has investors questioning if this is right time to sell.